42 / 51
Immunology 2018
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Page 105
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
1 5
t h
I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
W
ith a solid establishment of disease biomarkers, the consideration of clinical autoimmune type 1 diabetes (T1D) is now
pushed back to the presence of islet autoimmunity or insulitis with islet autoantibodies (iAbs) in peripheral blood before
clinical overt T1D appears. It is accepted that the classification of T1D is divided into 3 disease stages: Stage 1 is the presence of
two or more iAbs with a normal glucose metabolism, Stage 2 is the presence of two or more iAbs with an impaired Oral Glucose
Tolerance Test (OGTT) and Stage 3 is overt diabetes. The biomarker for islet autoimmunity is well known to be started with single
iAb (usually IAA or GADA) at early stage and further progressed to two or more iAbs. But unfortunately single iAb identified
by the current standard radio-binding assay (RBA) is not able to be adopted as an official biomarker for disease classification
since it is problematic for disease specificity and the rate of progression of diabetes in children with persistent single iAb is only
15% in 15 years across populations. We have recently developed, validated, and patented a new generation of iAb assays using
the technology of electrochemiluminescence (ECL). In addition to higher sensitivity and earlier identification of iAbs among
longitudinally followed young children from birth, the ECL assay has been demonstrated in multiple clinical trials to be more
disease specific. It is able to discriminate the high risk, high affinity iAbs from the low risk; low affinity iAbs generated in the RBA
that usually appear among subjects with a single iAb. The ECL assay can substantially refine the selection of single iAb positive
individuals at high risk and could be used as a reliable early biomarker for T1D islet autoimmunity.
Liping.yu@ucdenver.eduEarly identification for autoimmune type 1 diabetes
Liping Yu, Hilary High, and Dongmei Miao
Barbara Davis Center for Childhood Diabetes, University of Colorado, USA
Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-003